Table 2.

Summary of the ongoing clinical trials with PSMA PET/CT

(source: https://clinicaltrials.gov/)

Trial identifier number	Phase	status	PSMA tracer	Aim
NCT04987086	NA	Recruiting	68Ga-PSMA-11	(1) To evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced RCC, and to compare with that of ceCT. (2) To evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced RCC.
NCT05170555	NA	Recruiting	68Ga-PSMA-11	(1) To evaluate the uptake of 68Ga-PSMA in RCC compared to 18F-FDG. (2) To assess the feasibility of 177Lu-EB-PSMA-617 treatment in patients with the advanced RCC.
NCT03427476	I	Completed	18F-CTT1057	To test a novel diagnostic PET imaging agent, binding PSMA expressing tumors, for safety and biodistribution.
NCT03387514	II	Completed	18F-DCFPyL	To assess response to systemic therapy (anti-angiogenesis and/or immune-based therapies) in patients with mRCC comparing PSMA imaging with the conventional RECIST 1.1 criteria and histopathological endpoints (including isolation, enumeration, and staining of circulating tumor cells).
NCT03073395	I	Recruiting	68Ga-P16-093	(1) To evaluate the uptake of 68Ga-P16-093 in metastatic prostate and renal cancer. (2) Measurement of the whole-body biodistribution of 68Ga-P16-093 in prostate cancer patients to generate human radiation dosimetry data.
NCT04147494	Early I	Recruiting	68Ga-PSMA-11, 68Ga-FAPI-46	(1) To define the biodistribution of radiotracers in normal and cancer tissues of patients with various non-prostate malignancies, including RCC. (2) To evaluate whether 68Ga-PSMA-11 uptake correlates with the amount PSMA in excised cancer tissue.

ceCT contrast-enhanced Computed Tomography, mRCC metastatic Renal Cell Carcinoma, NA not applicable, PET/CT positron emission tomography/computed tomography, PSMA prostate-specific membrane antigen, Recist 1.1 Response Evaluation Criteria In Solid Tumors version 1.1., RCC Renal Cell Carcinoma